Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative therapies work by mimicking the physiological actions of GLP-1, a hormone produced by the gut in response to food. By activating GLP-1 receptors in the pancreas, these agents enhance insulin release and inhibit glucago

The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting substantial weight loss – they exhibit intriguing contrasts in their pharmacolo